Table 2. Pooled performance of various serological and radiological based non-invasive assessment of fibrosis in patients with alcoholic liver disease.
| Noninvasive test | Significant Fibrosis (F2-4) | Cirrhosis (F4) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Cut-off | AUROC | Sens/Spec % | PPV/NPV% | Cut-off | AUROC | Sens/Spec % | PPV/NPV% | ||
| Blood-based biomarkers for non-invasive assessment | |||||||||
| PGAA | >10 | 0.83 | 54/98 | 97/64 | >10 | 0.87 | 80/88 | 72/92 | |
| FibroTest | 0.85 | 0.58 | 0.88 | 67/87 | 60/90 | ||||
| ELFTM | 0.84 | 10.5 (F3-4) | 0.94 | 79/91 | 71/94 | ||||
| Image-based techniques for non-invasive assessment | |||||||||
| TE/fibroscan | |||||||||
| 1. AST <39 IU/TB <0.5 mg/dL | 6.9 | 0.87 | 80/77 | 78/79 | 12.1 | 0.92 | 85/84 | 97/51 | |
| 2. AST 39–75 IU/TB <0.5 mg/dL or AST <39 IU/TB 0.5–0.9 mg/dL | 8.1 | 0.88 | 89/64 | 46/94 | 15.4 | 0.93 | 82/82 | 90/71 | |
| 3. AST 39-75 IU/TB 0.5–0.9 mg/dL | 8.8 | 0.90 | 85/82 | 61/94 | 19.9 | 0.92 | 86/86 | 93/74 | |
| 4. AST >39 IU/TB >0.9 mg/dL | 11.6 | 0.89 | 83/79 | 30/98 | 25.9 | 0.90 | 81/80 | 79/82 | |
| ARFI | 1.27 | 0.84 | 77/85 | 89/70 | 1.65 | 0.89 | 89/84 | 36/99 | |
| 2D-SWE | 10.2 | 0.94 | 82/93 | 90/88 | 16.4 | 0.95 | 94/91 | 71/99 | |
| MRE | 2.59 | 0.81 | 78/78 | 83/83 | 4.0 | 0.98 | 100/92 | 68/100 | |
AST, aspartate aminotransferase; AUROC, area under receiver operator characteristic curve; ELF, Enhanced liver fibrosis; PGAA, Prothrombin index, gamma glutamyl transferase, Apolipoprotein A1 and α2 macroglobulin; TE, transient elastography; ARFI, acoustic radiation force imaging; 2D-SWE, two dimensional shear wave elastography; MRE, magnetic resonance elastography; PPV, positive predictive value; NPV, negative predictive value; TB, total bilirubin.